Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toborinone SCHEMBL7322759 | 1.00 | ADRB3 (0.49) | ADRB3KMT2AADRB2ADRB1HTR1A | |
| Toborinone SCHEMBL29856392 | 1.00 | ADRB3 (0.49) | ADRB3KMT2AADRB2ADRB1HTR1A | |
| Toborinone SCHEMBL7332263 | 0.99 | KMT2A (0.51) | ADRB3KMT2AADRB2ADRB1HTR1A | |
| SCHEMBL7330564 | 0.90 | KMT2A (0.51) | ADRB3KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7324649 | 0.90 | KCNH2 (0.44) | ADRB3KMT2AADRB2ADRB1HTR1A | |
| SCHEMBL6648856 | 0.90 | LMNA (0.47) | ADRB3KMT2AADRB2ADRB1KCNH2 | |
| Hydrochloric Acid SCHEMBL7379169 | 0.89 | KMT2A (0.50) | ADRB3KMT2AKCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL6649070 | 0.89 | KMT2A (0.50) | ADRB3KMT2AKCNH2KDM4E | |
| Hydrochloric Acid SCHEMBL7356845 | 0.89 | LMNA (0.46) | ADRB3KMT2AADRB2ADRB1KCNH2 | |
| Hydrochloric Acid SCHEMBL7330315 | 0.89 | LMNA (0.46) | ADRB3KMT2AADRB2ADRB1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2591806-A1 | Medicinal composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | claimed |
| CN-1813699-B | pharmaceutical composition | OTSUKA PHARMA CO LTD | 2012-04-18 | — | — | CN | claimed |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| CN-102149282-A | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2011-08-10 | — | — | CN | claimed |
| EP-2291084-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | Neurogesx, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009143297-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-0647447-A1 | Carbostyril derivatives as phosphodiesterase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-12 | — | — | EP | claimed |
| US-5401754-A | Agent for treating thrombosis and phosphodiesterase inhibitor | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-03-28 | — | — | US | claimed |
| WO-1995003802-A1 | AQUEOUS COMPOSITION | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-02-09 | — | — | WO | claimed |
| US-5385914-A | Cardiotonic carbostyril agents for treating heart ailments | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | claimed |
| EP-0355583-B1 | Cardiotonics | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | EP | claimed |
| WO-1994006427-A1 | CARBOSTYRIL DERIVATIVES AS ANTIARRHYTHMIC AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-31 | — | — | WO | claimed |
| US-5266577-A | Method of treating congestive heart failure using carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY LTD. (JP) | 1993-11-30 | — | — | US | claimed |
| EP-0531548-A1 | Carbostyril derivatives as anti-thrombotic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | claimed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | claimed |
| EP-0355583-A2 | Cardiotonics | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ADRB3 4025/4885KMT2A 2173/4885ADRB2 4334/4885 |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ADRB3 4025/4885KMT2A 2173/4885ADRB2 4334/4885 |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ADRB3 4025/4885KMT2A 2173/4885ADRB2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.